Chinese tourists flood Hong Kong for overpriced HPV vaccine | Healthcare Asia Magazine
, China

Chinese tourists flood Hong Kong for overpriced HPV vaccine

Supply is running out fast.

Mainland Chinese tourists are trooping to Hong Kong to get vaccinated against HPV, but many face disappointment due to rapidly depleting stocks.

A report by Xinhua revealed that there are already about 2 million consumers in the Mainland who choose to go to Hong Kong to inject Gardasil 9, a cervical cancer vaccine developed by Merck Pharmaceuticals.

The cost of the vaccine has more than tripled to HK$8,000 (about $1,000) and complaints have flooded the city’s consumer protection agency. The huge market demand has also spawned the industrial chain of :vaccination agencies” arranging trips to Hong Kong for women seeking the vaccine.

In some cases, clinics are failing to follow the prescribed schedule of shots. According to the optimal injection period recommended by Merck, the second injection needle has to be inoculated at least two months after the first injection After inoculation, the third needle can be inoculated after at least four months. In total, the three-injection vaccine needs to be inoculated within six months to one year to ensure maximum effectiveness.

However, due to low supply, some clinics are administering the 2nd injection over 8 months after the first injection, leading to an inoculation period of over 11 months.

Statistics show that over 2,000 people have not been vaccinated as scheduled, many of whom are women about to inject a second or third needle.

As a result, Hong Kong’s Consumer Council has received over 400 vaccine-related claims in the first four and a half months of the year, compared with 478 for all of 2017.

Pemindaian AI terkini meningkatkan diagnosa di Shin Kong Wu Ho-Su Memorial Hospital

Rumah sakit di Taiwan ini menggunakan teknologi endoskop yang dibantu AI untuk mendeteksi polip dan kamera resolusi tinggi untuk telemedis.

Kejeniusan dalam ‘SuperApps’ untuk perawatan kesehatan adalah akses dan jangkauan

Rumah sakit yang merangkul digitalisasi tetap unggul dalam layanan kesehatan.

Rumah Sakit Kanker Dharmais memimpin inovasi pelayanan kanker di Indonesia

Direktur Utama RS Kanker Dharmais Soeko Werdi Nindito Daroekoesoemo mengungkapkan teknologi canggih dan tujuh program unggulan untuk perawatan kanker.

Healthway Cancer Care Hospital memajukan perawatan holistik dengan harga yang wajar

Rumah sakit mengharapkan program kualitas dan kelangsungan hidup yang melayani keseluruhan perjalanan pasien.

MakatiMed menuju perawatan bedah presisi dengan sistem robotik Da Vinci Xi

Teknologi ini memungkinkan teknik invasif minimal dalam bidang urologi, hepatobilier, kardiovaskular, toraks, kebidanan dan ginekologi, serta bedah umum.

Indonesia memperluas dukungan solusi kesehatan menggunakan AI

Kolaborasi dengan Google Cloud sejalan dengan cetak biru pemerintah untuk transformasi kesehatan digital.

Indonesia merancang rencana induk untuk pengembangan kesehatan terpadu

Rencana induk sektor kesehatan negara (RIBK) selaras dengan mandat Undang-Undang Kesehatan Nomor 17 Tahun 2023.

The Medical City membuka jalan bagi integrasi AI dalam layanan kesehatan lokal dan penelitian dengan Lunit

AI telah diintegrasikan ke dalam layanan mamografi dan rontgen dada di jaringan rumah sakit ini.

Mayapada Healthcare Group meraih prestasi besar di Healthcare Asia Awards 2024

Pendekatan holistik yang dilakukan oleh rumah sakit tersebut mendorongnya maju dan menjadi standar industri.

Rumah Sakit Kanker Dharmais meraih dua kemenangan di Healthcare Asia Awards 2024

Sumber daya manusia yang kompeten, layanan, fasilitas, dan infrastruktur unggul membantu rumah sakit memberikan perawatan pasien yang sangat baik.